Glatiramer acetate 是髓鞘堿性蛋白的合成類似物和一種免疫調(diào)節(jié)劑，可用于多發(fā)性硬化癥的研究。Glatiramer acetate 顯示出與 MHC 分子強(qiáng)而雜亂的結(jié)合，因此與各種髓鞘抗原競爭，使其呈現(xiàn)給T細(xì)胞。Glatiramer acetate 作用的另一個(gè)方面是有效地誘導(dǎo)T輔助細(xì)胞 2 (Th2) 的特異性抑制細(xì)胞遷移到大腦并導(dǎo)致原位旁觀者抑制。

  體外研究：

   Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels^[3].
In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days^[3].